Expertise in
15
conditions

Dr. Milan G. Chheda

Neurology
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 

Overview

Milan Chheda is a Neurologist practicing medicine in Saint Louis, Missouri.

Dr. Chheda is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

He is actively involved in clinical research, co-authoring 59 peer reviewed articles and participating in 16 clinical trials. Dr. Chheda is currently accepting new patients.

Specialties

Neurology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish West County Hospital
Barnes Jewish Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Golden Rule
  • INSURANCE PLAN
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Washington University School of Medicine
4921 Parkview Pl, Saint Louis, MO 63110

Additional Areas of Focus

Dr. Chheda has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Longitudinal Study to Correlate Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
A Longitudinal Study to Correlate Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Device
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2026
Intervention Type: Device, Biological, Drug
Study Drugs: Personalized neoantigen DNA vaccine, Plasmid encoded IL-12
Study Phase: Phase 1
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
A Pilot Study of Temporally-modulated Pulsed Radiation Therapy to Reirradiate Recurrent IDH-mutant Gliomas After Prior External Beam Radiation Therapy
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Radiation
Study Phase: Not Applicable
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Drugs: rhIL-7-hyFc, Temozolomide
Study Phase: Phase 1/Phase 2
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Enrollment Status: Completed
Publish Date: November 21, 2025
Intervention Type: Drug, Radiation
Study Drugs: Epacadostat, Bevacizumab
Study Phase: Phase 2
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Biological, Device
Study Drug: Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Disulfiram, Copper Gluconate, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Radiation, Drug, Procedure
Study Drug: Avelumab
Study Phase: Phase 1
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drug: Tadalafil
Study Phase: Phase 1
View 9 Less Clinical Trials

59 Total Publications

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.
Journal: Nature cancer
Published: September 02, 2026
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.2 miles away)
314-454-6120
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Gutmann is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Gutmann is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Optic Glioma, Neurofibromatosis Type 1 (NF1), and Glioma. Dr. Gutmann is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

St. Louis Children's Hospital

1 Childrens Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-454-6120
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Renee Shellhaas is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Shellhaas is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Epilepsy in Children, West Syndrome, Spasmus Nutans, and Seizures. Dr. Shellhaas is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.2 miles away)
314-286-1967
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Holtzman is a Neurologist practicing medicine in Saint Louis, Missouri. Dr. Holtzman is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Primary Amyloidosis, Cerebral Amyloid Angiopathy, and Gastrostomy. Dr. Holtzman is currently accepting new patients.

Frequently Asked Questions about Dr. Milan G. Chheda

How do I make an appointment with Dr. Milan G. Chheda?

You can book an appointment with Dr. Milan G. Chheda by calling their office at 314-747-1171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Milan G. Chheda a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Milan G. Chheda is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Milan G. Chheda specialize in?

While Dr. Milan G. Chheda is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Milan G. Chheda participate in research or clinical trials?

Yes. Dr. Milan G. Chheda has published 59 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Milan G. Chheda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Milan G. Chheda accept my insurance?

Dr. Milan G. Chheda accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-747-1171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chheda's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile